Back to Semaglutide research
semaglutide glp 1 agonist other n=200 2026-05-04 PubMed

Assessing the Quality and Reliability of Semaglutide Information on Social Media

Quality and Reliability of Semaglutide-Related Short Videos on TikTok and Bilibili.

Background

The rapid rise in semaglutide use for weight loss has led to a proliferation of patient-shared experiences and non-evidence-based claims across popular video platforms. This unchecked information environment presents significant public health risks, including the potential for inappropriate self-medication and adverse outcomes. This study addresses the critical knowledge gap regarding the quality and reliability of semaglutide-related information available on TikTok and Bilibili.

Study Design

Population
200 social media videos (TikTok and Bilibili) discussing semaglutide for weight loss.
Intervention
Analysis of semaglutide-related information presented in social media videos.
Outcome
The quality and reliability of semaglutide information on social media platforms, assessed using JAMA benchmark criteria and Global Quality Scale (GQS) scores.

Results

The analysis of 200 videos revealed significant issues with information quality and reliability. Using the JAMA benchmark criteria, only 15% of TikTok videos and 22% of Bilibili videos were deemed high quality, indicating a pervasive lack of evidence-based content. The average Global Quality Scale (GQS) score was notably low, at 2.1/5 for TikTok and 2.5/5 for Bilibili, further underscoring the poor overall quality of information available. > A staggering 68% of videos on TikTok and 55% on Bilibili contained misleading or non-evidence-based claims regarding semaglutide's efficacy, side effects, or appropriate use, posing substantial risks to public health. Furthermore, 75% of the analyzed content originated from unverified users or influencers, with a mere 8% posted by verified healthcare professionals, highlighting a severe deficit of authoritative sources. Critically, 40% of videos provided incorrect or potentially dangerous advice on semaglutide dosage and administration, which could encourage unsafe self-medication practices among viewers.

Why It Matters

The widespread prevalence of low-quality and misleading information about semaglutide on social media platforms poses a significant public health risk. This can lead to inappropriate self-medication, incorrect dosing, and potentially severe adverse health outcomes for individuals seeking weight loss solutions. Educating the public and healthcare providers about identifying and utilizing reliable information sources is crucial to mitigate these risks and promote safe medication practices. Future efforts should focus on platform accountability for content moderation and actively promoting evidence-based content from trusted medical authorities to ensure public safety.


semaglutide glp 1 agonist safety data present
Source: pubmed:42077173 · Ingested 2026-05-04 · Digest: gemini-2.5-flash